University of Groningen
Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
Prof. dr. R.P.H. Bischoff, Prof. dr. A.J. van Gool, Dr. T.M. Luider, Prof. dr. R.A. Wevers
0031 (0)50 3633338
The BDC focuses on translating candidate biomarkers into validated clinical tests using highly specific, ultra-sensitive, high-throughput methodologies based on LC-MS/MS and immunoassays to analyse proteins, peptides and metabolites in complex biological samples. In its beginning, the BDC will focus on 3 major disease areas: Chronic Obstructive Pulmonary Disease (COPD), Alzheimer’s Disease (AD) and Type II Diabetes (T2D). The BDC is an open innovation network leveraging on the expertise of multiple analytical laboratories and multiple clinical centres. We collaborate closely with the group of Peter Horvatovich (member of the DTL) when it comes to data processing and data analysis.
- Quantitative LC-MS/MS based proteomics, peptidomics and metabolomics
- Clinical biomarker assays by NMR
- Biomarker discovery and validation
- Clinical chemistry
- Quantitative bioanalysis of proteins, peptides and metabolites
- Mass spectrometry based differential profiling
Expertise and Track Record
435000013 Metabolic differences induced by slowly and rapidly digestible starch with dr. M.G. Priebe (UMC Groningen)
The integration of technology-driven research with clinical applications is rather unique in the Netherlands as is the focus on biomarker validation rather than discovery. This allows for a direct translation of research results into multi-centric clinical validation studies. Our open innovation network should allow close interactions with other partners in the DTL.
- Quantitative LC-MS/MS based proteomics, peptidomics and metabolomics: Smuts, I., van der Westhuizen, F. H., Louw, R., Mienie, L. J., Engelke, U. F. H., Wevers, R. A., Mason, S., Koekemoer, G., and Reinecke, C. J. (2013) Disclosure of a putative biosignature for respiratory chain disorders through a metabolomics approach. Metabolomics 9, 379-391
- Rosenling, T., Stoop, M. P., Smolinska, A., Muilwijk, B., Coulier, L., Shi, S., Dane, A., Christin, C., Suits, F., Horvatovich, P. L., Wijmenga, S. S., Buydens, L. M. C., Vreeken, R., Hankemeier, T., van Gool, A. J., Luider, T. M., and Bischoff, R. (2011) The Impact of Delayed Storage on the Measured Proteome and Metabolome of Human Cerebrospinal Fluid. Clinical Chemistry 57, 1703-1711
- proton nuclear magnetic resonance spectroscopy. Clinical Chemistry 52, 1395-1405
- Clinical biomarker assays by NMR: Oostendorp, M., Engelke, U. F. H., Willemsen, M. A. A. P., and Wevers, R. A. (2006) Diagnosing inborn errors of lipid metabolism with Data processing and statistical analysis: Christin, C., Hoefsloot, H. C. J., Smilde, A. K., Hoekman, B., Suits, F., Bischoff, R., and Horvatovich, P. (2013) A Critical Assessment of Feature Selection Methods for Biomarker Discovery in Clinical Proteomics. Molecular & Cellular Proteomics 12, 263-276
- LC-MS/MS in biomarker discovery: Stoop, M. P., Rosenling, T., Attali, A., Meesters, R. J. W., Stingl, C., Dekker, L. J., van Aken, H., Suidgeest, E., Hintzen, R. Q., Tuinstra, T., van Gool, A., Luider, T. M., and Bischoff, R. (2012) Minocycline Effects on the Cerebrospinal Fluid Proteome of Experimental Autoimmune Encephalomyelitis Rats. J. Proteome Res. 11, 4315-4325
Bischoff is the responsible scientist for the Chromosome 5 team in a large-scale international collaboration termed the Chromosome-Centric Human Proteome Project (see http://www.c-hpp.org/);Bischoff is part of the COAST consortium of NWO-ACTS. For further information see www.biomac.nl under Annual Report 2012;Van Gool is a founding member of the DTL and responsible for biomarkers at TNO Healthy Living;Wevers heads the clinical chemistry department at the Radboud University Nijmegen Medical Center and is member of the Dutch Health Council (directory committee);Luider is involved in various national and European projects and initiatives.